Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | TSC1 |
Variant | R204H |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | TSC1 R204H does not lie within any known functional domains of the Tsc1 protein (UniProt.org). R204H is predicted to decrease interaction with Rac1 and increase interaction with tuberin by in silico analysis (PMID: 37063680), but has not been biochemically characterized and therefore, its effect on Tsc1 protein function is unknown (PubMed, Jun 2024). |
Associated Drug Resistance | |
Category Variants Paths |
TSC1 mutant TSC1 R204H |
Transcript | NM_000368.5 |
gDNA | chr9:g.132921871C>T |
cDNA | c.611G>A |
Protein | p.R204H |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001406607.1 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
NM_001406594.1 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
NM_001406608.1 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
NM_001406605.1 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
NM_000368 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
NM_001162426 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
XM_006717271.1 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
NM_001406602.1 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
NM_001406601.1 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
NM_001406597.1 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
XM_017015096 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
XM_017015097 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
XM_017015098.1 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
NM_000368.5 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
NM_001406596.1 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
NM_001406609.1 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
XM_017015096.1 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
XM_005272211 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
XM_006717271 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
NM_001406603.1 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
NM_001162426.2 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
XM_011518979.2 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
NM_001406606.1 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
NM_001406592.1 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
NM_001406593.1 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
XM_011518979 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
NM_001406598.1 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
XM_017015098 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
XM_011518979.3 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
XM_017015097.1 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
NM_000368.4 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
XM_005272211.1 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
NM_001406595.1 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
NM_001406604.1 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
NM_001162426.1 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
NM_001406599.1 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
NM_001406600.1 | chr9:g.132921871C>T | c.611G>A | p.R204H | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|